Onconova Therapeutics Revenue, Profits - ONTX Annual Income Statement

Add to My Stocks
$0.49 $0.04 (7.55%) ONTX stock closing price Sep 17, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Onconova Therapeutics stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 impacts the ONTX stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Onconova Therapeutics profit and loss statement for 2017 total to $26.51M. This line item shows that the operating expenses has decreased compared with last year. Also check: Onconova Therapeutics assets and Onconova Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Onconova Therapeutics Revenues or Net Sales
-5.54M11.45M-4.75M46.19M1.48M
Cost Of Goods Sold (COGS)-------
Onconova Therapeutics Gross Profit
-5.54M11.45M-4.75M46.19M1.48M
Research & Development Expense19.11M20.07M25.89M49.42M50.18M52.76M22.62M
Selling General & Admin Expense7.4M9.17M9.53M15.11M16.79M15.7M6.43M
Income Before Depreciation Depletion Amortization-25.73M-23.7M-23.97M-63.74M-62.22M-22.27M-27.57M
Depreciation Depletion Amortization-------
Non Operating Income1.65M4.05M-0.03M-0.03M--1.29M
Interest Expense-----8.6M-
Onconova Therapeutics Pretax Income
-24.07M-19.65M-24M-63.77M-62.12M-29.91M-26.29M
Provision for Income Taxes-------
MinorityInterest---0.04M-0.11M-0.01M--
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-24.09M-19.66M-24.02M-63.79M-62.55M-29.91M-26.29M
Extraordinary Items & Discontinued Operations-------
Onconova Therapeutics Profit/ Loss (Net Income)
-24.09M-19.66M-23.97M-63.68M-62.54M-29.91M-26.29M
Average Shares used to compute Diluted EPS9M4.43M2.27M2.17M1.06M1.27M-
Average Shares used to compute Basic EPS9M4.43M2.27M2.17M1.06M1.27M-
Income Before Nonrecurring Items-24.09M-19.67M-23.98M-63.68M-62.56M-29.91M-
Income from Nonrecurring Items-------
Onconova Therapeutics Earnings Per Share Basic Net
-2.68-4.44-10.50-29.40-61.20-23.60-
Onconova Therapeutics Earnings Per Share Diluted Net
-2.68-4.44-10.50-29.40-61.20-23.60-
EPS Diluted Before Nonrecurring Items-2.68-4.44-10.50-29.40-61.20-23.60-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Celgene financial analysis

Onconova Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this year of 2017. Our Onconova Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-24.09M for ONTX stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The ONTX financials along with Onconova Therapeutics historical stock prices provide a lot of details about the firm.

Onconova Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
22.92
Dividend Yield
0%